After two-drug treatment, all 14 in one colon cancer group had 10% or less cancer left at surgery; 13 had none.
Agenus' UNICORN trial showed that 14 pMMR/MSS colon cancer patients treated with BOT+BAL had 10% or less cancer left at surgery, with 13 having no cancer. The trial met its primary endpoint with a 36% major pathologic response rate. No patients had cancer recurrence, with 100% 12-month event-free survival. Agenus plans a Phase 3 ROBBIN trial based on these results.
How this was made
The 30-second read
Why it matters
The UNICORN Phase 2 data provides the first peer‑reviewed evidence of deep responses in MSS colon cancer, supporting the upcoming Phase 3 ROBBIN trial.
Market read
Positive trial data may trigger a short‑term rally in AGEN and influence peer biotech valuations.
What to watch
Regulatory timeline and competition from other checkpoint combos could temper upside.
Background
Agenus (NASDAQ: AGEN) is developing botensilimab (anti‑CTLA‑4) and balstilimab (anti‑PD‑1) for solid tumors.
Ticker impact
Agenus reported positive Phase 2 UNICORN trial results for its botensilimab + balstilimab combo in MSS colon cancer.
likely upward pressure as market prices in the favorable efficacy data.
Phase 2 data with 100% 12‑month event‑free survival and high pathologic response is material for a biotech.
Market effects
Strengthens the MSS colon‑cancer immunotherapy niche and may lift peer biotech stocks.
US biotech sector could see modest gains.
Limited to oncology investors; no broad market effect.
Counterpoint
Skeptics may question durability of response and lack of long‑term survival data.
Key entities
- CompanyAgenus Inc.
Immuno‑oncology biotech developing BOT and BAL.
- DrugBOT (botensilimab)
Fc‑enhanced anti‑CTLA‑4 antibody.
- DrugBAL (balstilimab)
Anti‑PD‑1 antibody.
